08.15.25
I. Paul Singh, MD; Constance Okeke, MD, MSCE; and Zarmeena Vendal, MD, convene to discuss the latest updates on drug delivery and procedural pharmaceuticals in glaucoma treatment—specifically regarding the intracameral bimatoprost implant (Durysta, AbbVie) and iDose TR (travoprost intracameral implant) 75 mcg (Glaukos). They each explain the role of these treatments in their practices and how to identify the noncompliant patients who are the best candidates for this intervention. They also review safety data behind these treatments and share pearls for getting started. Editorially independent content supported with advertising by Glaukos.
View full description +
Subscribe
08.15.25
Sustained Drug Delivery in Interventional GlaucomaI. Paul Singh, MD; Constance Okeke, MD, MSCE; and Zarmeena Vendal, MD
06.26.25
Survey Says: Choosing Treatment for a High-Risk PatientI. Paul Singh, MD; Erin Sieck, MD; and Arkadiy Yadgarov, MD
05.23.25
Career Change: Making the Vision Come to Life • Private Practice Versus AcademiaZahra Ali, MD; and Devang L. Bhoiwala, MD
03.19.25
Survey Says: Proceeding After Unsuccessful TreatmentI. Paul Singh, MD; Manjool Shah, MD; and Ticiana De Francesco, MD,
02.24.25
Impact of Selective Laser Trabeculoplasty on Diurnal IOP FluctuationCatherine Johnson, MD, MPH
Show More